Medical Oncology Department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif 94805, France.
Vascular endothelial growth factor (VEGF) is, to date, the key element in the pathogenesis of renal cell carcinoma (RCC). VEGF pathway activation is responsible for the recruitment, migration, and expansion of endothelial cells, with this angiogenesis tumor model being characteristic of RCC. Different strategies have been developed for almost a decade to block the VEGF pathway in this setting. Four different compounds were approved for metastatic RCC (mRCC) in the past 6 years: bevacizumab, sunitinib, sorafenib, and pazopanib. Axitinib and tivozanib are also promising compounds under evaluation. The revolution in the management and prognosis of patients with mRCC is ongoing.
Written by:
Albiges L, Salem M, Rini B, Escudier B. Are you the author?
Reference: Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33.
doi: 10.1016/j.hoc.2011.04.006
PubMed Abstract
PMID: 21763969
UroToday.com Renal Cancer Section
